Last reviewed · How we verify
Oral Fedratinib
JAK2 inhibitor
JAK2 inhibitor Used for Myeloproliferative neoplasm.
At a glance
| Generic name | Oral Fedratinib |
|---|---|
| Also known as | FEDR |
| Sponsor | Celgene |
| Drug class | JAK inhibitor |
| Target | JAK2 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Fedratinib is a potent and selective inhibitor of JAK2, which is involved in the signaling of various cytokines and growth factors.
Approved indications
- Myeloproliferative neoplasm
Common side effects
- Thrombocytopenia
- Anemia
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms (PHASE2)
- Fedratinib in Combination With Nivolumab (PHASE2)
- Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL) (PHASE2)
- Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms (PHASE1)
- A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) (PHASE1, PHASE2)
- A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis (PHASE2)
- To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213) (PHASE2)
- Effect of SAR302503 on ECG Activity in Patients With Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |